ReviewInternational journal of nanomedicine2026
Harnessing Natural Extracellular Vesicles to Combat Age-Related Diseases: From Aging Drivers to Therapeutic Opportunities.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a complex biological process that leads to a growing burden of age-related diseases (ARD). Cellular senescence, which involves irreversible cell cycle arrest and the release of senescence-associated secretory phenotype (SASP), plays a central role in aging and the development of ARD. Natural extracellular vesicles (NEVs) refer to vesicles that derived from cells, organs and body fluids without artificial interventions. In recent years, NEVs have gained attention as mediators of intercellular communication, and showed multifunctional potential in regulating cellular senescence and ARD. On the one hand, these vesicles are capable of spreading senescence signals by transferring molecules such as miRNAs, proteins, and DNA fragments. On the other hand, NEVs derived from animal cells, body fluids, plant cells, and bacteria have demonstrated potential anti‑aging effects. This review synthesizes research findings from the past two decades, with a particular focus on studies published in the last five years that elucidate the molecular mechanisms by which NEVs regulate cellular senescence. This review aims to summarize various applications (biomarkers, drug delivery vehicles, direct therapeutic agents) of NEVs in major ARD, including neoplasms, cardiovascular diseases, neurodegenerative disorders, bone diseases, and diabetes. Several challenges including standardizing production, targeted delivery, mechanism exploration, and clinical translation are also discussed. Combining bioengineering, multi-omics technologies, and improved model systems could be important to fully utilize the potential of NEVs, and offer precise, safe, and effective strategies for ARD therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.